Date: 2018-05-25
Type of
information: Recruitment of the first patient
phase: 1
Announcement: recruitment of the first patient
Company: Thrombogenics (Belgium)
Product: THR-149
Action
mechanism:
- kallikrein inhibitor/peptide. THR-149 is a novel plasma kallikrein inhibitor. This bicyclic peptide (Bicycle®) has been identified as a lead candidate in the alliance between ThromboGenics and Bicycle Therapeutics. Bicycles are a novel class of small molecule medicines designed to overcome many of the limitations of existing drug modalities. They can be used as standalone therapeutic entities or coupled to deliver a variety of therapeutic payloads, and exhibit the affinity and exquisite target specificity usually associated with antibodies but in a small molecule format enabling rapid tissue penetration and flexible routes of administration.
Disease: diabetic macular edema
Therapeutic
area: Ophtalmological diseases
Country: USA
Trial
details:
- This study is conducted to evaluate the safety of a single intravitreal injection of THR-149. (NCT03511898)
Latest
news:
- • On May 25, 2018, ThromboGenics announced that it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME . Preclinical studies have demonstrated the potency and efficacy of bicyclic peptide inhibitors of PKal, such as THR-149, supporting its progression into clinical trials for the potential treatment of DME, via a VEGF-independent mechanism.
- The Phase 1 study (THR-149-001) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-149 in patients with DME. Approximately 18 patients will be enrolled.
- Initial results from the THR-149-001 study are anticipated in mid-2019.
Is
general: Yes
